FGFR kinase inhibitors and pharmaceutical uses
US11192890B2 · kind B2 · utility
2Cited by
0References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 2, 2018 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Mar 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.